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We report a nonepisodic autosomal dominant (AD) spinocerebellar ataxia (SCA) not caused by a nucleotide repeat
expansion that is, to our knowledge, the first such SCA. The AD SCAs currently comprise a group of16 genetically
distinct neurodegenerative conditions, all characterized by progressive incoordination of gait and limbs and by
speech and eye-movement disturbances. Six of the nine SCAs for which the genes are known result from CAG
expansions that encode polyglutamine tracts. Noncoding CAG, CTG, and ATTCT expansions are responsible for
three other SCAs. Approximately 30% of families with SCA do not have linkage to the known loci. We recently
mapped the locus for an AD SCA in a family (AT08) to chromosome 19q13.4-qter. A particularly compelling
candidate gene, PRKCG, encodes protein kinase C g (PKCg), a member of a family of serine/threonine kinases.
The entire coding region of PRKCG was sequenced in an affected member of family AT08 and in a group of 39
unrelated patients with ataxia not attributable to trinucleotide expansions. Three different nonconservativemissense
mutations in highly conserved residues in C1, the cysteine-rich region of the protein, were found in family AT08,
another familial case, and a sporadic case. The mutations cosegregated with disease in both families. Structural
modeling predicts that two of these amino acid substitutions would severely abrogate the zinc-binding or phorbol
ester–binding capabilities of the protein. Immunohistochemical studies on cerebellar tissue from an affected member
of family AT08 demonstrated reduced staining for both PKCg and ataxin 1 in Purkinje cells, whereas staining for
calbindin was preserved. These results strongly support a new mechanism for neuronal cell dysfunction and death
in hereditary ataxias and suggest that there may be a common pathway for PKCg-related and polyglutamine-related
neurodegeneration.
Introduction
The nonepisodic autosomal dominant (AD) spinocerebel-
lar ataxias (SCAs) share the clinical features of progres-
sive incoordination of gait, dysarthria, dysphagia, and
limb dysmetria, which are often associated with abnor-
mal eye movements. Additional features, such as mental
retardation, retinopathy, peripheral neuropathy, or my-
oclonus, distinguish some subtypes of the hereditary
ataxias (Rosenberg 1995; Mariotti and DiDonato 2001;
also see “Hereditary Ataxia Overview,” by T.D.B., in
GeneReviews, available at the GeneTests Home Page).
The clinical presentation reflects degeneration of the cer-
ebellar cortex and various other regions of the CNS. The
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incidence of the disease is ∼1–5/100,000, with an av-
erage age at onset in the 3rd decade of life.
Trinucleotide repeat expansions, (CAG)n, that encode
polyglutamine tracts are responsible for SCA1, SCA2,
SCA3, SCA6, SCA7, and SCA17, whereas expanded
CTG, ATTCT, and noncoding CAG repeats are respon-
sible for SCA8, SCA10, and SCA12, respectively. In
North American populations, ∼30% of families with
SCA do not have linkage to the known loci (Moseley
et al. 1998). We recently mapped the locus for an AD
SCA, without other defining clinical features, in a fami-
ly (AT08) to a 22-cM region on chromosome 19q13.4-
qter (Brkanac et al. 2002). A maximum two-point LOD
score of 2.57 was obtained for marker D19S254 at re-
combination fraction 0, and a multipoint LOD score of
4.72 was obtained at D19S926. Among the 1300 genes
and ESTs in the minimal region listed in the National
Center for Biotechnology Information (NCBI) database
on December 20, 2001 (for the NCBI Map Viewer, see
the Entrez Genome View Web site), one particularly com-
pelling candidate gene was PRKCG (MIM 179680), en-
coding protein kinase C g (PKCg).
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Figure 1 Organization of PRKCG and corresponding protein. A, Functional domains, showing the conserved (C) and variable (V) regions.
The amino acid (aa) boundaries of the regions are shown as predicted in the SMART database. The mutations found in the present study are
indicated by arrows. The position of a reported mutation in retinitis pigmentosa (Al-Maghtheh et al. 1998) is indicated by an arrowhead, and
the relative position of the rat agu mutation (Craig et al. 2001) is indicated by an asterisk. B, Exonic organization. C, Amino acid sequence
alignment in the Cys2 region, showing striking evolutionary conservation of PKCg and other isozymes of PKC at three mutation sites found
in the present study (shown in gray).
PKCg is a member of the conventional subgroup of
a serine/threonine kinase family (Coussens et al. 1986;
Knopf et al. 1986) that plays a role in such diverse
processes as signal transduction, cell proliferation and
differentiation, synaptic transmission, and tumor pro-
motion (e.g., see Tanaka and Nishizuka 1994; Zeid-
man et al. 1999; Newton 2001). The PKC isozymes
differ in their tissue distributions and responsiveness
to calcium and phospholipids (e.g., see Tanaka and
Nishizuka 1994; Ho et al. 2001). The amino-terminal
regulatory domain of PKCg contains two cysteine-rich
regions (Cys1 and Cys2), collectively termed “C1”
(each of which interacts with two zinc ions and pro-
vides high-affinity diacylglycerol [DAG]/phorbol ester
binding), and a Ca2-sensitive region, termed “C2”
(figs. 1A and 1B) (for review, see Newton 2001). The
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carboxyl-terminal catalytic domain contains kinase
and substrate-recognition regions.
Tissue-expression patterns and rodent models strong-
ly suggested PKCg as a candidate for the chromosome
19q13.4-qter ataxia locus. In vertebrates, the expression
of PKCg is high in brain and spinal cord (Saito et al.
1988), with particularly high expression in Purkinje cells
of the cerebellar cortex (Barmack et al. 2000). PKCg-
knockout mice have mildly abnormal gait and incoor-
dination (Abeliovich et al. 1993; C. Chen et al. 1995)
associated with abnormal persistence of multiple-climb-
ing-fiber innervation onto Purkinje cells (C. Chen et al.
1995). The spontaneously arising nonsense mutation in
PKCg in agu rats produces a recessive parkinsonian-like
movement disorder accompanied by progressively more
impaired, staggering gait (Craig et al. 2001). Transgenic
mice that overexpress ataxin 1 containing an expanded
polyglutamine tract develop pathological changes in Pur-
kinje cells and a progressive ataxia similar to that seen
in patients with SCA1 (Burright et al. 1995; Clark et al.
1997). In these SCA1 transgenic mice, PKCg protein con-
centration is decreased and mislocalized from the Pur-
kinje cell dendritic membrane into cytoplasmic vacuoles
(Skinner et al. 2001). For these reasons, we evaluated
PRKCG for DNA sequence alterations in family AT08.
Subjects and Methods
Patients
Subjects and families referred to the Medical Genetics
Clinic at the University of Washington Medical Center or
seen in the Neurology Clinic at the Puget Sound Veterans
Affairs Hospital were evaluated by one of us (T.D.B.) and
were included in the study if they met a clinical diagnosis
of unexplained cerebellar ataxia. Subjects gave informed
consent for blood draw and DNA studies under protocols
approved by the University of Washington institutional
review board. Families AT08 and AT29 have a relatively
uncomplicated form of cerebellar ataxia and no apparent
decrease of life span. Additional clinical details of family
AT08 can be found elsewhere (Brkanac et al. 2002). Ped-
igrees of family AT08 and another multiplex family in
which PRKCG mutations were found are shown in fig-
ure 2.
Mutation/Polymorphism Detection
DNA was isolated from peripheral blood, and the
18 exons and splice junctions of the PRKCG gene
were PCR amplified with AmpliGold Taq (Applied
Biosystems), using the following nine intronic primer
pairs (Integrated DNA Technologies): exons 1 and 2,
forward (ctgcctttggctcttcct) and reverse (cagcctccaccc-
tcctga) (1,016 bp); exon 3, forward (cgctctctctttccaat-
ttt) and reverse (gaggaggagaaccaggtgt) (203 bp); ex-
ons 4 and 5, forward (caaggcaggaggaaaagata) and re-
verse (acaagtgccttgggtcag) (542 bp); exon 6, forward
(gcttggaactcttgattgct) and reverse (ccactaggaccctcaga-
tca) (310 bp); exons 7–9, forward (acctccagcaccaag-
gat) and reverse (atgtgtggggaattgaagac) (1,059 bp);
exons 10 and 11, forward (ttgggagcatttccttatcg) and
reverse (ctcgccctaaactcagaatc) (825 bp); exons 12–14,
forward (gtctgatagttggcggtggt) and reverse (cagtgcca-
agctcacctg) (896 bp); exons 15 and 16, forward (ggga-
agagcttgtgctgaaa) and reverse (tcaggaatgggagcattttt)
(1,880 bp); and exons 17 and 18, forward (ttctctgggtct-
acctgtcc) and reverse (ttagtggtgtggtctctgga) (932 bp).
The amplification protocol included an initial dena-
turation at 95C for 5 min; 32 cycles of 94C for 30
s, 56C (or 54C in some fragments) for 45 s, and 72C
for 60 s; and a final extension at 72C for 10 min.
PCR-amplified fragments were cleaned by exonuclease
I and shrimp alkaline phosphatase digestion using Exo-
SAP-IT (USB Corporation). Direct DNA sequencing of
the purified fragments was performed as described else-
where (D. H. Chen et al. 2002) with either the same
forward primers as in the PCR amplifications or the
following primers within the amplimers: exon 2 (ctgg-
attcctgggtctgaag), exons 8 and 9 (cttccaatgtctttgcctct),
exons 13 and 14 (atccagccactgaccttct), exon 16 (ggca-
tccgagataggaaatg), and exon 18 (cagacaccatgaagcatg-
aata). For confirmation of the sequence alterations,
exon 4 was also sequenced in reverse.
Radioisotope dideoxy sequencing with two bases (wild-
type C and mutant T) was performed to evaluate the
cosegregation of ataxia and the mutation in family AT08
and to screen 96 normal control individuals for a possible
polymorphism. The forward primer for exon 4 was end-
labeled with [g32]P by a T4 kinase reaction, and sequenc-
ing was performed with the AmpliCycle Sequencing Kit
(Applied Biosystems). The sequencing products were elec-
trophoresed at 50C on 6% polyacrylamide gels contain-
ing 7 M urea.
The single-nucleotide substitutions 355TrC and
383GrA altered the restriction endonuclease digestion
patterns of HaeIII and MwoI, respectively. RFLP anal-
yses with these enzymes (New England Biolabs) were
performed on 260-bp exon 4 fragments (PCR amplified
with the forward primer given above and the reverse
primer atttcccggaacccagac) from 96 normal control in-
dividuals, under the conditions suggested by the man-
ufacturer. Restriction fragments were separated on 3%
agarose gels. HaeIII digestion generated fragments of
11, 25, 36, and 188 bp in wild type and 11, 25, 36,
58, and 130 bp in 355TrC mutants. MwoI digestion
generated fragments of 55, 59, 72, and 74 bp in wild
type and 55, 59, and 146 bp in 383GrA mutants. An
additional 96 normal control individuals were evalu-
ated for all three sequence changes in exon 4 by fluo-
rescence-labeling sequencing methods.
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Figure 2 Pedigrees of two multiplex kindreds in which PRKCG mutations were identified. Asterisks denote subjects who provided blood
samples. Symbols representing clinically affected individuals are blackened, and deceased individuals are indicated by a slash mark. Age at death
(d.), approximate age at onset of symptoms (o.), and current age (c.) are shown, in years, above and to the left of the relevant symbols.
Protein-Structure Modeling
Residues 100–153 of the nuclear magnetic resonance
(NMR) structure of PKCg (i.e., only the ordered residues;
see Xu et al. 1997) were used for the molecular dynamics
(MD) simulations. Initial mutant structures were created
with the Insight97 program (Accelrys) by replacing the
original residues with the best-fitting rotamers. The pro-
tein structures were inserted into a box of TIP3P waters
with boundaries 10 A˚ away from any protein atom.
Simulations were performed with the Amber program
(Pearlman et al. 1995), using the Cornell95 force field
(Cornell et al. 1995), a constant dielectric . Zincp 1.0
ions were modeled using the cationic dummy method of
Pang et al. (2000). The particle-mesh Ewald method pro-
vided a proper treatment of the long-range electrostatic
forces, and a cutoff of 10 A˚ was applied to van der Waals
forces. Bonds were constrained with the Shake algorithm.
Each solvated protein was energy minimized (5,500 cy-
cles) and was then heated to 298 K (50 ps) and equili-
brated (150 ps). This was followed by a 1.0-ns MD
simulation (NVE ensemble; 1-fs time steps), to study the
behavior of the proteins.
Immunohistochemistry
Microtome sections (5 mm) were cut from paraffin-em-
bedded sections of cerebellar tissue. For enhancement of
the immune reaction, the slides were pretreated by boiling
in Na citrate for both ataxin 1 and ubiquitin staining and
by protease digestion for PKCg staining. Standard avidin-
biotin complex immunochemical staining was performed.
Mouse monoclonal anti-PKCg (ZyMed Laboratories),
rabbit polyclonal anti–ataxin 1 (ZyMed Laboratories),
rabbit anti-calbindin (Sigma-Aldrich), and rabbit anti-
ubiquitin (East Acres Biologicals) were used at dilutions
of 1:20, 1:50, 1:2,000, and 1:8,000, respectively.
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Figure 3 Sequence chromatograms for portions of PRKCG exon 4, showing heterozygous mutations in affected individuals from three
families with SCA as compared to control individuals. A, A CrT transition in nucleotide 301 in family AT08. B, A TrC transition in nucleotide
355 in family AT29. C, A GrA transition in nucleotide 383 in family AT117. The relevant nucleotides are highlighted by squares. Predicted
amino acids are also shown under the corresponding nucleotide sequence.
Results
Identification of PRKCG Mutations in Patients
with Ataxia
The entire coding region of PRKCG was sequenced
in genomic DNA from an affected individual (IV-13)
in family AT08 (fig. 2). A CrT transition in nucleotide
301, counted from the start codon in mRNA (GenBank
accession number NM_002739), was detected in exon
4, predicting substitution of hydrophilic tyrosine for
hydrophobic histidine at position 101 (H101Y) (fig.
3A). All individuals from whom DNA samples were
obtained were screened for the mutation. The mutation
segregated with disease in all nine other affected mem-
bers of the family. Two clinically unaffected at-risk in-
dividuals in their 20s also inherited the mutation (not
indicated on the pedigree, for consideration of confi-
dentiality). The remaining 13 at-risk individuals and 4
spouses had the wild-type sequence. This histidine res-
idue, in the Cys2 region, is evolutionarily conserved in
all mammals and invertebrates studied and in all Cys2
regions in the PKC family (fig. 1C). The CrT nucle-
otide change was not found in 192 normal control in-
dividuals (384 chromosomes). In comparing the residue
numbers in the literature, we noticed that there is a
discrepancy between the numbering shown for rat
PKCg by Knopf et al. (1986) and the NCBI database
(GenBank accession number NM_002739). Knopf et
al. inserted a space at position 14 in the rat molecule
to allow alignment of the residues of several PKC iso-
forms. Because some authors referred directly or in-
directly to the article by Knopf et al., beyond residue
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Figure 4 MD studies of wild-type and mutant Cys2 regions of PKCg. A,Three-dimensional structure of the Cys2 region of wild-type PKCg
with phorbol acetate bound. H101 is a ligand in the first zinc binding site; zinc is shown in red. S119 is close to the second zinc binding site, as
well as the phorbol acetate binding site. G128 is also in the vicinity of the phorbol acetate binding site; Ca positions of S119 and G128 are indicated
by white spheres. B, Fluctuations of protein backbone coordinates per residue, expressed as root-mean-square deviation (RMSD) (in A˚) for wild
type and three mutants. Note the instability of the H101Y mutant in comparison to wild type and the two other mutants. C, Differences in average
structures, calculated as distance between Ca positions (in A˚) per residue between wild type and each of the three mutants. Note the global shift
of the structure in the H101Y mutant and the shifts in the phorbol ester binding site in the G128D mutant. WTp wild type; *p first zinc binding
site; ^ p second zinc binding site; ∼ p phorbol binding site.
13, their numbering is one higher for the rat and human
PKCg proteins. We used the numbering given in the
NCBI database.
PRKCG was then sequenced in 39 additional subjects
with ataxia, 27 with positive family histories and 12
with apparently sporadic disease. All subjects had pre-
viously tested negative for expansions in the genes for
SCA1, SCA2, SCA3, and SCA6. Twenty-seven subjects
had also tested negative for abnormal alleles of SCA7
and SCA8. Two other mutations in exon 4 were detected
that affect highly conserved residues in the Cys2 region
(figs. 3B and 3C). A TrC transition in nucleotide 355,
predicting a serine-to-proline substitution at residue 119
(S119P), was found in an affected woman and her af-
fected son and daughter (mean age at onset 42 years,
range 35–51 years; family AT29 in fig. 2). A GrA tran-
sition in nucleotide 383, predicting a glycine-to-aspar-
tate substitution at residue 128 (G128D), was found in
a 55-year-old man with onset in his early 20s who had
no family history of ataxia (family AT117); his father
and mother died at ages 83 and 54 years, respectively.
The serine and glycine residues are also conserved in all
mammalian Cys2 regions and most PKC family mem-
bers (fig. 1C). One hundred ninety-two control samples
(384 chromosomes) were tested, and none exhibited ei-
ther of these two single-nucleotide changes.
Solution-Structure Modeling
Residues involved in zinc and phorbol ester binding in
the C1 domain of rat PKCg and PKCd were previously
identified by in vitro binding assays (Quest et al. 1994;
Kazanietz et al. 1995; Xu et al. 1997) and were confirmed
by NMR spectroscopy (Xu et al. 1997) and x-ray crys-
tallography (Zhang et al. 1995). We compared the mo-
lecular structure of each of the three mutants to the wild-
type structure through MD simulations in water at room
temperature for the Cys2 region of PKCg (fig. 4). Because
the phorbol ester binding site is partially collapsed in the
PKCg NMR structure when it is devoid of a ligand (Xu
et al. 1997), the MD simulations were repeated with the
following modification: the conformation of this binding
site was altered into the conformation seen in the crystal
structure of the homologous PKCd phorbol acetate com-
plex (Zhang et al. 1995). Phorbol acetate fit perfectly in
this new PKCg conformation. This shortcut was applied
because the transition between these two conformational
states typically takes longer than 1 ms. The results of both
sets of simulations were virtually identical; however, only
the second set is appropriate for the evaluation of phorbol
ester binding. For conciseness, only the results of the
second set of simulations are shown in figure 4. Our so-
lution-structure modeling predicts that two of the three
mutations detected in patients with ataxia would have a
dire effect on the function of the PKCg protein. The
H101Y protein conformation fluctuated wildly during the
simulation, with protein backbone atoms moving 13.0 A˚,
especially in the Zn1 and phorbol ester binding sites,
whereas the wild type and the two other mutant proteins
were stable (fig. 4B). Our modeling predictions are con-
sistent with previous in vitro functional studies of the
Cys2 region of protein kinase C. A deletion study (Quest
et al. 1994) of the phorbol binding domain of rat PKCg
identified this residue (which was denoted as “His102”)
as critical for both zinc coordination and phorbol ester
binding. Substitution of glycine for histidine at the anal-
ogous position in rat PKCd completely abolished phorbol
binding (Kazanietz et al. 1995). To our knowledge, res-
idues 119 and 128 have not been studied previously in
mutational analyses. Although residue 128 is not within
the phorbol ester binding site, our structural modeling
predicted that the substitution of aspartate for glycine
indirectly changes the shape of the binding site, with a
maximum shift of 11.0 A˚ for Leu124 (fig. 4C). Hence, it
is likely that the G128D mutation reduces the binding
affinity of phorbol esters. Only a local change in protein
backbone position was observed for the substitution of
proline for serine at residue 119. Thus, there is no obvious
structural explanation for the deleterious effects of this
mutation. However, the observation that Ser119 is con-
served in PKCg in all mammals studied, as well as in
PKCg homologues in Caenorhabditis elegans and Dro-
sophila brain and most other PKC isoforms, argues for
the functional importance of this residue (fig. 1C).
Immunohistochemical Studies
We examined PKCg immunoreactivity in cerebellar tis-
sue from an affected person (II-7) in family AT08 who
died of a ruptured left-middle cerebral artery aneurysm
at age 66 years (fig. 2). Limited postmortem brain was
available, and there was no information on the time be-
846 Am. J. Hum. Genet. 72:839–849, 2003
tween death and fixation of tissues. There was selective
marked loss of Purkinje cells in the cerebellum (Brkanac
et al. 2002). Immunohistochemical studies showed that
the residual Purkinje cells all stained very poorly for
PKCg relative to control cerebellum, although there was
cell-to-cell variability (figs. 5A and 5B). Because PKCg
has been reported to be reduced in Purkinje cells in SCA1
transgenic mice (Skinner et al. 2001), we were interested
in determining the expression of ataxin 1 in the cerebel-
lum of the patient with mutant PKCg. The majority of
Purkinje cells showed lack of staining for ataxin 1, and
only a minority retained faint cytoplasmic staining (figs.
5C and 5D). Staining was normal for calbindin, a pro-
tein that is highly expressed in Purkinje cells (figs. 5E
and 5F), demonstrating that the observations with PKCg
and ataxin 1 were unlikely to be nonspecific sequelae of
cell dysfunction and death. A hallmark pathological fea-
ture of several SCAs is the aggregation of the expanded
protein in ubiquitin-positive nuclear inclusions; such in-
clusions were not detected in the patient whom we stud-
ied (not shown).
Discussion
We present here evidence supporting a new mechanism
for nonepisodic AD hereditary ataxia, apparently un-
related to a nucleotide repeat expansion. The missense
mutations (H101Y, S119P, and G128D) in the Cys2 re-
gion of the C1 domain of PKCg appear to cause a dis-
order that, on clinical grounds, is indistinguishable from
other “uncomplicated” SCAs. The patients with muta-
tions in PRKCG whom we studied displayed an adult-
onset cerebellar ataxia without any differentiating fea-
tures, such as cognitive decline, visual or other sensory
loss, axial myoclonus, or peripheral neuropathy. The
mean age at onset in the 14 persons with ataxia was 33
years (range 10–51 years), and there was no evidence
for a shortened life span. Examination of the two ped-
igrees in figure 2 shows a trend for earlier age at onset
in the youngest generation. However, this observation
may be an artifact. With increased awareness of the dis-
ease in the families, the age at diagnosis in the younger
generation may be more accurate than the recollected
age at onset in the older generation. Full sequencing of
the coding region and UTRs of PRKCG did not reveal
a trinucleotide repeat tract. Although it is theoretically
possible that there is a repeat expansion in an intron, it
is highly unlikely that an undetected expansion is present
in each of the three mutant alleles.
In the 40 clinical cases studied that were not attributed
to SCA1, SCA2, SCA3, and SCA6, mutations in PKCg
are responsible for 7.5% of cases (3/40; 2 of 28 families
and 1 of 12 sporadic cases). PKCg is within the minimal
region for SCA14, a disorder described in a single Jap-
anese family and characterized by early-onset axial my-
oclonus (Yamashita et al. 2000). Although the phenotype
of the families that we studied does not include this sign,
it is possible that a mutation in a different portion of
PKCg is responsible for SCA14. As additional families
are studied, a better clinical picture of the range of the
complete phenotype of this type of ataxia will be devel-
oped, and genotype-phenotype correlations can then be
evaluated.
There are substantial differences in the phenotypes
conferred by different PKCg mutations in humans,
mice, and rats. In a candidate-gene analysis for retinitis
pigmentosum type 11 (RP11), a neurodegenerative ret-
inal disorder that maps to chromosome 19q13.4, an
identical mutation, R659S, in the catalytic domain was
reported in four unrelated individuals with familial
retinitis pigmentosa (Al-Maghtheh et al. 1998). This
alteration, affecting a conserved residue, segregated
with disease in the two families available for study.
However, no mutation was found in six other families
with RP11 (Al-Maghtheh et al. 1998; Dryja et al.
1999). None of the PKCg-mutation carriers in the fam-
ilies reported here has experienced unusual visual loss,
and an electroretinogram performed as part of a pre-
vious clinical evaluation of the affected sporadic case
(in family AT117) was normal.
The phenotype of the recessive agu rat resembles that
of SCA only in clumsy gait (Craig et al. 2001). None
of the affected individuals in our study show features of
parkinsonism, such as tremor, rigidity, or bradykinesia.
The agu mutation results in a protein truncated to 280
amino acids, missing the entire catalytic domain of PKCg.
The amino-terminal regulatory portion of PKCg was not
studied to determine if it could be detected in neurons
or if it aggregated improperly. Although the loss of PKCg
kinase activity likely contributes to this neurological phe-
notype, the differences in the phenotypes of the knockout
mouse and the homozygous agu-mutant rat suggest a role
for a dysfunctional amino-terminal moiety of the protein.
It is interesting that the neurological phenotype of the
heterozygous mutation in the patients described in the
present article appears to be more severe than that of the
knockout mouse (Abeliovich et al. 1993; C. Chen et al.
1995). This observation makes it unlikely that the en-
zyme is rate limiting or that the intracellular concentra-
tion of PKCg is critical for some downstream process.
Although the phenotypic difference may be an artifact of
the different life spans of the two species, an alternative
hypothesis is that the presence of the mutant protein
produces more-toxic effects on the cells than does the
absence of the protein. Perhaps the mutant proteins have
a dominant negative effect by competing with the wild-
type protein for attachment sites on the membrane or for
substrate binding. PKCg translocates between the plasma
membrane and the cytosol during its activation cycle
(Newton 2001). This process involves binding of DAG
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Figure 5 Reduced immunoreactivity for PKCg and ataxin 1 in an ataxic patient from family AT08 who carries the H101Y mutation.
A and B, PKCg immunohistochemistry. The scattered surviving Purkinje cells in a postmortem cerebellar section showed reduced but variable
staining for antibody to PKCg (A), compared with intense staining in membrane and dendrites from an age-matched control (B). C and D,
Ataxin 1 immunohistochemistry. The majority of Purkinje cells from the same ataxic patient showed no immunostaining for ataxin 1, but
a minority of cells were weakly positive. Control Purkinje cells were intensely stained in cytoplasm (D). E and F, Calbindin immunohis-
tochemistry. Staining for calbindin was similar in the ataxic patient and the control individual, demonstrating that the loss of PKCg and
ataxin 1 did not represent nonspecific decreased protein synthesis. Scale bar p 75 mm.
and Zn2. The N-terminal region of PKCg regulates the
C-terminal kinase activity. Therefore, disruption of zinc
and DAG binding by H101Y and G128D may indirectly
alter the enzyme’s phosphorylation function. It is also
possible that the mutations exert their toxic effect by
increasing the intracellular concentration of Zn2(Koh
2001). Our modeling study did not identify an effect of
S119P on zinc or DAG binding sites. Perhaps the sub-
stitution of proline for serine affects the molecule’s sol-
ubility, a property that cannot be predicted by solution-
structure modeling. In addition, the clustering of all three
mutations in exon 4 may suggest a common mechanism
for pathogenicity; for example, this region of PKCg may
be critical for interaction with another functional protein.
Current understanding of the pathogeneses of poly-
glutamine-expansion diseases is evolving. For SCA1, it
appears that the presence of mutant ataxin 1 in the nu-
cleus is necessary and sufficient for development of dis-
ease and neuronal cell death (Klement et al. 1998). Al-
though a hallmark pathological feature of SCA1 is ag-
gregation of the expanded protein along with compo-
nents of the ubiquitin-conjugation system in nuclear
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inclusions, neither aggregation nor sequestration of the
protein is required. The observation that PKCg is reduced
and abnormally localized in Purkinje cells of SCA1 trans-
genic mice (Skinner et al. 2001) raises the possibility that
it plays an essential role in the development and/or pro-
gression of this disorder. Our observation of decreased
expression of ataxin 1 in Purkinje cells containing a mu-
tation in PKCg suggests that there may be a common
pathway for neurodegeneration of these and other types
of SCA.
Note added in manuscript.—After this article was ac-
cepted for publication, an article describing a missense
mutation in the fibroblast growth factor 14 gene in a
single family with an ataxia syndrome was published by
van Swieten et al. (2003).
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